Xing Du

Associate Researcher

After Xing obtained his Ph. D at Shanghai Institute of Biochemistry and Cell Biology, China, he joined NCI, where he conducted studies on the cancer immunotherapy target discovery, antibody based immunotoxin construction and development, immunotoxin cancer therapy and its mechanism to induce cancer cell death, cancer resistance and strategies to overcome such resistance. Later he joined HICCC at CUMC to develop novel mouse model for triple negative breast cancer, and identify synthetic lethal interaction against genetic feature of various cancer pathways, such PTEN loss, Ras mutation, Rb, etc. He then joined Dr Mukherjee’s lab, and are exploring novel treatment for AML and MDS including targeted therapy, dietary therapy and immunotherapy, identifying genetic regulations in myeloid malignancies and the interaction between mesenchymal cell and hematopoietic stem cells.

In his free time, he likes to play bridge, listen to music, and watch movie.


Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR, Bareja R, Ma Y, Harris EM, Sboner A, Beltran H, Rubin MA, Mukherjee S & Cantley LC. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 570, 499-503 (2018)

Kalinsky K, Zheng T, Hibshoosh H, Du X, Mundi P, Yang J, Refice S, Feldman SM, Taback B, Connolly E, Crew KD, Maurer MA, Hershman DL. Proteomic modulation in breast tumors after metformin exposure: results from a “window of opportunity” trial. Clin Transl Oncol. 2017;19(2):180-188.

Reid R, Du X, Sunjevaric I, Rayannavar V, Dittmar J, Bryant E, Maurer M, and Rothstein R. A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells. Genetics. 2016;204(2):807-819.

Ying-Ka Ingar Lau, Xing Du, Vinayak Rayannavar, Benjamin Hopkins, Jacquelyn Shaw, Eliana Bessler, Tiffany Thomas, Maira M. Pires, Megan Keniry, Ramon E. Parsons, Serge Cremers, Matthias Szabolcs, Matthew A. Maurer. Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget. 2014;5(21):10503-17.

Xing Du, Laiman Xiang, Crystal Mackall, and Ira Pastan. Killing of resistant cancer cells with low Bak by a combination of an anti-mesothelin immunotoxin and a TRAIL receptor 2 agonist antibody. Clinical Cancer Research. 2011, 15;17:5926-34.

Xing Du, Richard J. Youle, David FitzGerald, Ira Pastan. Pseudomonas exotoxin A-mediated apoptosis is Bak-dependent and preceded by the degradation of Mcl-1. Molecular and Cellular Biology. 2010, 30(14):3444-3452.

Xing Du, Richard Beers, David Fitzgerald and Ira Pastan. Differential cellular internalization of anti-CD19 and CD22 immunotoxins results in different cytotoxic activities. Cancer Research. 2008, 68(15):6300-6305.

Xing Du, Satoshi Nagata, Tomoko Ise, Maryalice Stetler-Stevenson, and Ira Pastan. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia and B-cell non-Hodgkin’s lymphoma as a target of immunotoxins. Blood. 2008, 111(1), 338-343.

Xing Du, Mitchell Ho, Ira Pastan. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. Journal of Immunotherapy. 2007, 30(6), 607-613.